Navigation Links
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs

CUPERTINO, Calif., May 3, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2012. Excluding the accelerated recognition of deferred revenue described below, DURECT's reported revenues would have been $5.8 million for the three months ended March 31, 2012 (as compared to $8.6 million for the same period in 2011) and reported net loss would have been $4.6 million for the three months ended March 31, 2012 (as compared to a net loss of $6.4 million for the same period in 2011).  Total revenues as reported under GAAP were $41.2 million and net income as reported under GAAP was $30.8 million for the three months ended March 31, 2012; these figures include the accelerated recognition of $35.4 million in deferred revenue associated with upfront fees previously received under terminated collaboration agreements.  This $35.4 million in revenue is non-recurring and has no cash flow impact for the quarter.

(Logo: March 31, 2012, we had cash and investments of $26.4 million, compared to cash and investments of $30.8 million at December 31, 2011."This quarter was dominated by the POSIDUR™ clinical trial results and partnership terminations.  However, we continued to make progress with our development programs and we have recently reinforced the protection of our pipeline through 13 patent issuances and 2 patent allowances involving major and/or partnered programs that extend patent protection in large market jurisdictions to 2025 or beyond," stated James E. Brown, D.V.M., President and CEO of DURECT.  "In particular, we now have issued U.S. patents covering REMOXY® and our other ORADUR®-based opioid programs that extend to at least 2025 as well as an issued European patent providing coverage to at least 2023."

Update of Programs:

  • REMOXY (oxycodone) Extended-Release Capsules CIIPfizer has efforts underway to resolve the issues raised in the REMOXY Complete Response Letter and stated in its earnings call on January 31, 2012 that it expects to conduct two bioavailability studies in the second quarter of 2012 and then meet with the FDA in the third quarter to discuss next steps.  The issues raised in the Complete Response Letter relate primarily to manufacturing.
  • REMOXY, an investigational drug, is a unique long acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT's ORADUR technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse.

  • POSIDUR (SABER®-Bupivacaine) Post-Operative Pain Relief Depot. Preparation of our briefing package is well underway for our scheduled pre-NDA meeting with the FDA in the summer of 2012, with a potential NDA submission later in the year, depending on FDA feedback. 
  • POSIDUR is our post-operative pain relief depot that utilizes our patented SABER technology to deliver bupivacaine to provide up to three days of pain relief after surgery.  We currently hold worldwide commercialization rights to POSIDUR following the notice given in the first quarter of 2012 by Hospira and Nycomed to terminate their collaborations related to the program.

  • Transdermal Development Candidates.
    DURECT has two transdermal products that are in mid- to late-stage development with features that may be superior to currently available patches.  TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to 7 days from a single application; this compares favorably against existing fentanyl patches which are substantially larger and typically effective for 2-3 days.  ELADUR, for topical neuropathic conditions such as post-herpetic neuralgia (PHN), is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to three days from a single application; existing lidocaine patches for this condition can be worn for 12 hours with a rest period of 12 hours during which time many patients experience breakthrough pain.  Pfizer's termination of the ELADUR collaboration in the first quarter of 2012 returns to DURECT the rights to develop and commercialize ELADUR worldwide.  We are in discussions with potential partners regarding licensing development and commercialization rights to these two transdermal programs to which we hold worldwide rights.
  • ORADUR-ADHD Program.  We are developing a drug candidate (ORADUR-ADHD) based on DURECT's ORADUR Technology for the treatment of Attention Deficit Hyperactivity Disorder. This drug candidate is intended to provide once-a-day dosing with added tamper resistant characteristics to address common methods of abuse and misuse of these types of drugs.
    We and Orient Pharma have completed several Phase I pharmacokinetic studies with multiple formulations.  Based on information from those studies, we are continuing to evaluate our lead formulations.  Orient Pharma is our licensee for certain Asian and South Pacific countries, while we retain the rights to the rest of the world.
  • Relday™ (Risperidone Program).  In July 2011, we signed a development and license agreement with Zogenix to develop Relday, a product candidate targeting the antipsychotic market.  Zogenix expects to initiate clinical studies for Relday in patients with schizophrenia in 2012.  Relday is a proprietary, long-acting (once-monthly) injectable formulation of 0.5 mL of risperidone using DURECT's SABER controlled-release formulation technology in combination with Zogenix's DosePro® needle-free, subcutaneous drug delivery system.  The existing long-acting injectable risperidone product, which achieved $1.6 billion in global net sales in 2011, requires twice-monthly, 2 mL intramuscular injections with a 21 gauge or larger needle. 
  • Feasibility Projects and Other Activities.  During the first quarter of 2012, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth by our collaborators and are worthy of further development.
    The Zogenix program, described above, was one such project which has matured into a development and license agreement.
  • Business Development Activities.  We have multiple programs that may potentially be licensed over the next 12-18 months.  These include POSIDUR, TRANSDUR-Sufentanil, ELADUR, ORADUR-ADHD (territories outside certain Asian and South Pacific markets), as well as various internal programs which we have not described publicly in detail.
  • Earnings Conference CallA live audio webcast of a conference call to discuss first quarter 2012 results will be broadcast live over the internet at 4:30 p.m. Eastern Time on May 3 and is available by accessing DURECT's homepage at and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

    About DURECT CorporationDURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit

    NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

    DURECT Forward-Looking Statement The statements in this press release regarding the potential bioavailability studies for REMOXY, potential regulatory meetings and submissions for REMOXY and POSIDUR, anticipated clinical trials (including timing and results) for Relday and our other drug candidates, the potential benefits and uses of our drug candidates, collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including rejection of meeting requests, requests for additional information or product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K on March 2, 2012 under the heading "Risk Factors."DURECT CORPORATIONSTATEMENTS OF COMPREHENSIVE INCOME (LOSS) (in thousands, except per share amounts)(Unaudited)Three months ended March 31, 20122011Collaborative research and development and other revenue

    $38,328$ 5,512Product revenue, net

    2,8573,092Total revenues

    41,1858,604Operating expenses:Cost of product revenues

    1,4611,401Research and development

    5,6349,880Selling, general and administrative

    3,2803,716Total operating expenses

    10,37514,997Income (loss) from operations

    30,810(6,393)Other income (expense):Interest and other income

    2140Interest expense

    (2)(4)Net other income

    1936Net Income (loss)

    $30,829$(6,357)Net income (loss) per shareBasic $ 0.35$ (0.07)Diluted$ 0.35$ (0.07)Weighted-average shares used in computing net income (loss) per shareBasic 87,54787,270Diluted87,56887,270Total comprehensive income (loss)

    $30,826$(6,343) DURECT CORPORATIONCONDENSED BALANCE SHEETS (in thousands)As ofAs ofMarch 31, 2012December 31, 2011(1)(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $ 7,537$ 8,896Short-term investments

    15,12819,535Short-term restricted investments

    -367Accounts receivable


    3,2333,252Prepaid expenses and other current assets

    1,4881,803Total current assets

    30,30137,301Property and equipment, net


    6,3996,399Intangible assets, net

    4953Long-term investments

    3,2241,530Long-term restricted Investments

    501501Other long-term assets

    288288Total assets

    $ 43,703$ 49,196LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $ 615$ 1,274Accrued liabilities

    3,7084,884Contract research liability

    6651,361Deferred revenue, current portion

    3127,372Total current liabilities

    5,30014,891Deferred revenue, noncurrent portion

    1,71430,090Other long-term liabilities

    715738Stockholders' equity

    35,9743,477Total liabilities and stockholders' equity

    $ 43,703$ 49,196(1) Derived from audited financial statements. 





    SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
    3. DURECT to Participate in Upcoming Healthcare Conferences
    4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
    5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
    6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
    7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
    8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
    9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    10. DURECT to Present at the Jefferies Healthcare Conference
    11. DURECT Announces Resignation of Chief Medical Officer
    Post Your Comments:
    (Date:3/24/2017)... 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was valued at ... registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent graft system ... market during the study period. Continue Reading ... ... ...
    (Date:3/24/2017)... -- Research and Markets has announced the addition ... report to their offering. ... Pain Management in the U.S.: ... physical pain, emphasizing consumer survey analysis, including trends over time. ... who have selected illnesses/conditions strongly associated with physical pain and ...
    (Date:3/24/2017)... , March 24, 2017 News Commentary ... Medical cannabis products around ... Research, Inc., projects that the global medical cannabis market will reach a ... is a major market for the new growing industry. By the ... to legally buy and sell medical cannabis. More conservative states like ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
    (Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
    (Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the ... huge impact on businesses and individual consumers alike. Laboratories can maximize their profit ... value anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey ...
    (Date:3/23/2017)... NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of ... kids do not brush their teeth the minimum two times a day that dentists recommend. ... students missing 51 million hours of school and adults missing 164 million hours of work ...
    (Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the perfect ... comes to maintaining good health. Every day, two kidneys filter about 120 to 150 ... of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health ...
    Breaking Medicine News(10 mins):